Table 2:
Ongoing Clinical Trials of Anti-Adhesion Agents in Sickle Cell Disease
| Drug | Study Title | Mechanism of Action | Clinical Phase | NCT Number | Sponsor |
|---|---|---|---|---|---|
| Crizanlizumab | Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Adult Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) |
Anti-adhesive (anti-P- selectin agent) |
Phase 2 | NCT03264989 | Novartis |
| Rivipansel | Efficacy and Safety of Rivipansel (GMI- 1070) in the Treatment of Vaso- Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease |
Anti-adhesive (pan- selectin inhibitor) |
Phase 3 | NCT02187003 | Pfizer |
| Sevuparin | Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD |
Anti-adhesive (binds to P- and L-selectins, fibronectin, thrombospondin and von Willebrand factor) |
Phase 2 | NCT02515838 | Modus Therapeutics AB |